{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:02:05Z","timestamp":1787497325069,"version":"build-2736575974"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,24]]},"DOI":"10.7759\/cureus.99997","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:12:16Z","timestamp":1766578336000},"source":"Crossref","is-referenced-by-count":1,"title":["Reversible Heart Failure After Anthracycline and Alkylating Agent Chemotherapy"],"prefix":"10.7759","author":[{"given":"Amresh","family":"Gul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahid","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.00026","article-title":"Cardiotoxicity of anthracyclines","volume":"7","author":"Cardinale D","year":"2020","unstructured":"Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of anthracyclines. Front Cardiovasc Med. 2020, 7:26. 10.3389\/fcvm.2020.00026","journal-title":"Front Cardiovasc Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab843","article-title":"A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer","volume":"43","author":"Lewinter C","year":"2022","unstructured":"Lewinter C, Nielsen TH, Edfors LR, et al.. A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer. Eur Heart J. 2022, 43:2562-9. 10.1093\/eurheartj\/ehab843","journal-title":"Eur Heart J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-024-07322-w","article-title":"Understanding cardiac events in breast cancer (UCARE): pilot cardio-oncology assessment and surveillance pathway for breast cancer patients","volume":"207","author":"Cronin M","year":"2024","unstructured":"Cronin M, Lowery A, McInerney V, et al.. Understanding cardiac events in breast cancer (UCARE): pilot cardio-oncology assessment and surveillance pathway for breast cancer patients. Breast Cancer Res Treat. 2024, 207:283-91. 10.1007\/s10549-024-07322-w","journal-title":"Breast Cancer Res Treat"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1242596","article-title":"Anthracycline-induced cardiotoxicity: mechanisms, monitoring, and prevention","volume":"10","author":"Qiu Y","year":"2023","unstructured":"Qiu Y, Jiang P, Huang Y. Anthracycline-induced cardiotoxicity: mechanisms, monitoring, and prevention. Front Cardiovasc Med. 2023, 10:1242596. 10.3389\/fcvm.2023.1242596","journal-title":"Front Cardiovasc Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2016.017","article-title":"Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity","volume":"31","author":"Chung WB","year":"2016","unstructured":"Chung WB, Youn HJ. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity. Korean J Intern Med. 2016, 31:625-33. 10.3904\/kjim.2016.017","journal-title":"Korean J Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2021.22.9.2847","article-title":"The role of lisinopril and bisoprolol to prevent anthracycline induced cardiotoxicity in locally advanced breast cancer patients","volume":"22","author":"Wihandono A","year":"2021","unstructured":"Wihandono A, Azhar Y, Abdurahman M, Hidayat S. The role of lisinopril and bisoprolol to prevent anthracycline induced cardiotoxicity in locally advanced breast cancer patients. Asian Pac J Cancer Prev. 2021, 22:2847-53. 10.31557\/APJCP.2021.22.9.2847","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh TA","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021, 42:3599-726. 10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2019.2952","article-title":"Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis","volume":"4","author":"Oikonomou EK","year":"2019","unstructured":"Oikonomou EK, Kokkinidis DG, Kampaktsis PN, Amir EA, Marwick TH, Gupta D, Thavendiranathan P. Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Cardiol. 2019, 4:1007-18. 10.1001\/jamacardio.2019.2952","journal-title":"JAMA Cardiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001062","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022, 145:e876-94. 10.1161\/CIR.0000000000001062","journal-title":"Circulation"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-024-00259-5","article-title":"How to utilize current guidelines to manage patients with cancer at high risk for heart failure","volume":"10","author":"Bloom M","year":"2024","unstructured":"Bloom M, Alvarez-Cardona JA, Ganatra S, Barac A, Pusic I, Lenihan D, Dent S. How to utilize current guidelines to manage patients with cancer at high risk for heart failure. Cardiooncology. 2024, 10:63. 10.1186\/s40959-024-00259-5","journal-title":"Cardiooncology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac270","article-title":"2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery","volume":"43","author":"Halvorsen S","year":"2022","unstructured":"Halvorsen S, Mehilli J, Cassese S, et al.. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022, 43:3826-924. 10.1093\/eurheartj\/ehac270","journal-title":"Eur Heart J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.51038","article-title":"Cardio-oncology: managing cardiovascular complications of cancer therapies","volume":"15","author":"Sharma R","year":"2023","unstructured":"Sharma R, Kashyap J, Olanrewaju OA, et al.. Cardio-oncology: managing cardiovascular complications of cancer therapies. Cureus. 2023, 15:e51038. 10.7759\/cureus.51038","journal-title":"Cureus"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad196","article-title":"Erratum to: 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO), and the International Cardio-Oncology Society (IC-OS): Developed by the Task Force on Cardio-oncology of the European Society of Cardiology (ESC)","volume":"44","year":"2023","unstructured":"Erratum to. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO), and the International Cardio-Oncology Society (IC-OS): Developed by the Task Force on Cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J. 2023, 44:1621. 10.1093\/eurheartj\/ehad196","journal-title":"Eur Heart J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana JC","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A, et al.. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014, 27:911-39. 10.1016\/j.echo.2014.07.012","journal-title":"J Am Soc Echocardiogr"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/417081-reversible-heart-failure-after-anthracycline-and-alkylating-agent-chemotherapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:12:17Z","timestamp":1766578337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/417081-reversible-heart-failure-after-anthracycline-and-alkylating-agent-chemotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.99997","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,24]]}}}